Skip to search formSkip to main contentSkip to account menu

AZD 8931

Known as: AZD-8931, AZD8931 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies in the treatment of HER2-positive breast cancer… 
2016
2016
PurposeAZD8931 is an orally bioavailable, reversible tyrosine kinase inhibitor of EGFR, HER2, and HER3 signaling. The Phase II… 
2015
2015
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling network is frequently de-regulated… 
Highly Cited
2014
Highly Cited
2014
Modest up-regulation of either HER-ligands or receptors has been implicated in acquired endocrine resistance. AZD8931, a dual… 
2014
2014
Fibroblasts in the tumour stroma (cancer-associated fibroblasts) influence tumour progression and response to therapeutics… 
2014
2014
SummaryAim AZD8931 is an oral equipotent inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling. This Phase I, open… 
2014
2014
IntroductionEpidermal growth factor receptor (EGFR) overexpression has been associated with prognostic and predictive value in… 
2013
2013
Deregulation of HER family signaling promotes proliferation and tumor cell survival and has been described in many human cancers… 
Highly Cited
2010
Highly Cited
2010
Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2…